Gilead going strong at 20

06/23/2007 | San Francisco Chronicle

On Gilead Sciences' 20th anniversary, analysts said the Bay Area biotech is in a strong position to remain independent and expand into new treatment areas. Gilead, the nation's dominant seller of HIV drugs, had sales of $3 billion in 2006, and some analysts are predicting substantial growth in revenue this year.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC